Sector ratings Vertex Pharmaceuticals Incorporated

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 10/04/2026 BST			5-day change	1st Jan Change
436.27 ^USD	-2.35%		-0.56%	-3.77%

04-10	RBC Trims Price Target on Vertex Pharmaceuticals to $541 From $543, Keeps Outperform Rating	MT
04-09	Evercore ISI Adjusts Vertex Pharmaceuticals PT to $535 From $530, Maintains Outperform Rating	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
VERTEX PHARMACEUTICALS INCORPORATED	111B		AA
ELI LILLY AND COMPANY	841B		A
JOHNSON & JOHNSON	574B		BBB
ABBVIE INC.	368B		AA
ROCHE HOLDING AG	320B		AA			-		-
ASTRAZENECA PLC	318B		A
MERCK & CO., INC.	300B		A
NOVARTIS AG	295B		AAA
AMGEN INC.	189B		A
GILEAD SCIENCES, INC.	173B		AA
NOVO NORDISK A/S	168B		A
PFIZER INC.	153B		A
BRISTOL-MYERS SQUIBB COMPANY	120B		A
GSK PLC	117B		AA
SANOFI	114B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	89.72B		AA
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
TAKEDA PHARMACEUTICAL COMPANY LIMITED	56.91B		AA
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	55.4B		AA
BAYER AG	46.27B		AA
Average	223.6B		AA
Weighted average by Cap.			AA